e 4031 has been researched along with erythromycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD | 1 |
| Beck, J; Bode, C; Brunner, M; Franke, G; Hartmann, M; Koren, G; Odening, KE; Perez Feliz, S; Zehender, M; Ziupa, D | 1 |
2 other study(ies) available for e 4031 and erythromycin
| Article | Year |
|---|---|
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2004 |
Pronounced effects of HERG-blockers E-4031 and erythromycin on APD, spatial APD dispersion and triangulation in transgenic long-QT type 1 rabbits.
Topics: Action Potentials; Animals; Animals, Genetically Modified; Erythromycin; Female; Heart; Long QT Syndrome; Piperidines; Pyridines; Rabbits | 2014 |